Navigation Links
BioMarin Announces Second Quarter 2011 Financial Results
Date:7/28/2011

and Amortization (EBITDA) adjusted to exclude non-cash stock compensation expense, contingent consideration expense and certain nonrecurring material items (adjusted EBITDA).  

The following tables detail the reconciliation of non-GAAP to GAAP financial metrics:

Reconciliation of GAAP Net Income (Loss) to Non-GAAP Adjusted EBITDA(in millions)(unaudited)Three Months EndedJune 30, Six Months EndedJune 30, Year EndingDecember 31, 2011 NOTES2011201020112010Guidance GAAP Net Income (Loss)$ (5.1)$ (0.5)$ (9.4)$   0.7 $(43) - $(33) Interest expense, net1.3

1.6

2.6

2.8

6Income tax expense3.9

1.1

8.7

1.7

14Depreciation6.3

4.4

12.7

8.4

25Amortization1.0

0.9

1.9

1.0

4EBITDA 7.47.516.514.6 6 - 16 Stock-based compensation10.6

9.2

21.0

17.7

45Gain on sale of equity investments-(0.9)

-Contingent consideration

(1)

(4.1)

0.8

(4.6)

1.5

(2)Adjusted EBITDA$ 13.9$ 17.5$ 32.9$ 32.9 $49 - $59 (1)  Represents the changes in the fair value of contingent acquisition consideration payable for the period.   BioMarin believes that this non-GAAP information is useful to investors, taken in conjunction with BioMarin's GAAP information because it provides additional information regarding the performance of BioMarin's core ongoing business, Naglazyme, Kuvan, Aldurazyme and Firdapse and development of its pipeline.  By providing information about both the overall GAAP financial performance and the non-GAAP measures that focus on continuing operations, the company believes that the additional information enhances investors' overall understanding of the company's business and prospects for the future.  Further, the company uses both the GAAP and the non-GAAP results and expectations internally for its operating, budgeting and financial planning purposes and uses th
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Foundation today announced it has established a relief fund ... weather that has gripped much of the nation. AARP and ... to support these emergency relief efforts AARP and AARP Foundation ... up to $500,000 in aid. The matching program will be ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
(Date:1/15/2014)... , January 15, 2014 BreedIT ... the exclusive worldwide distributor of highly sophisticated agro-breeding solutions ... January 7, 2014, the Company,s board of directors appointed ... as its new member of the board. ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
(Date:4/18/2014)... Hopkins University School of Medicine researchers have been awarded ... diabetes, Novo Nordisk announced this month. Of the 110 ... Obesity Biologics Science Forum Program, only four projects were ... researchers. They are Jonathan Powell, M.D., Ph.D.; G. William ... Jonathan Powell, a professor of oncology, will use his ...
(Date:4/18/2014)... release is available in French . ... revolutionize surgical practice and regenerative medicine. A team led ... Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur from the ... 13), has just demonstrated that the principle of adhesion ... vivo to repair soft-tissue organs and tissues. This easy-to-use ...
(Date:4/17/2014)... pain relief targets that could be used to ... King,s College London made the discovery when researching ... of the body. , Dr Marzia Malcangio said: ... pain generation and our findings could help chemotherapy ... One potential side effect of some chemotherapy drugs ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... - New Hayfever Relief Product Based on Acupressure ... , - With Photo , ... it,s believed that,it now affects as many as 1 in 4 ... either complete misery with symptoms such as reduced,concentration, runny nose and ...
... Improvement Firm Recognizes Efforts in Patient SatisfactionSOUTH BEND, Ind., ... Press Ganey Associates, Inc., is proud to recognize all ... improving the quality of care they provide."The doctors, nurses, ... to improve quality, and they deserve to be commended," ...
... urged to prevent head, neck injuries , , SUNDAY, May ... help prevent head and neck injuries related to recreational ... year in the United States, about 1.5 million people ... and nearly 12,000 are treated for neck fractures, according ...
... Support the Nancy Davis Foundation for Multiple Sclerosis LOS ... the world,s most exclusive super sport cars, donated the ... to support the Nancy Davis Foundation for Multiple Sclerosis ... charity event at the Hyatt Regency Century Plaza in ...
... thwart hospital ,superbugs, viruses and mold, scientists say ... paint kills disease-causing bacteria, mold, fungi and viruses, said ... claim their paint, which can be used in homes, ... so-called "superbugs," antibiotic-resistant microbes that are found in hospitals ...
... free workshops with an emphasis on smoking cessation to raise public ... in order to improve their quality of life. , ... ... consecutive year, May 2009 has been designated Stroke Awareness Month. During ...
Cached Medicine News:Health News:'Qu-Chi' Acupressure Band Gives Hayfever Misery the Elbow 2Health News:'Qu-Chi' Acupressure Band Gives Hayfever Misery the Elbow 3Health News:Press Ganey Supports National Hospital Week 2Health News:Press Ganey Supports National Hospital Week 3Health News:Ladders, Swings and More Can Cause Peril 2Health News:First U.S. Lamborghini Gallardo LP 560-4 Spyder Auctioned at Race to Erase MS Charity Event 2Health News:Health Care Professionals Offer Free Consultations for National Stroke Awareness Month 2
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Finesse II electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
... 950, the first High Frequency Desiccator with Cut. ... half of the unit is a high frequency ... popular Aaron 900. The other half is a ... power and coag capabilities plenty of power ...
Medicine Products: